Patents by Inventor Timothy J. Falla
Timothy J. Falla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10376557Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: GrantFiled: August 17, 2016Date of Patent: August 13, 2019Assignee: Helix Biomedix Inc.Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
-
Publication number: 20170157196Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: ApplicationFiled: August 17, 2016Publication date: June 8, 2017Applicant: HELIX BIOMEDIX, INC.Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
-
Patent number: 9511042Abstract: The invention relates to small molecules having biological and therapeutic activity. Particularly, the invention relates to small molecules having lipolytic and anti-adipogenic activity. Two examples of such molecules are 4-methyl-2-(octanoylamino) pentanoic acid and N-isopentyloctanamide. The invention further relates to methods of preventing or treating skin conditions such as cellulite using small molecules having lipolytic and anti-adipogenic activity.Type: GrantFiled: June 28, 2011Date of Patent: December 6, 2016Assignee: HELIX BIOMEDIX INC.Inventors: Timothy J. Falla, Lijuan Zhang
-
Patent number: 9447143Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: GrantFiled: November 3, 2014Date of Patent: September 20, 2016Assignee: HELIX BIOMEDIX INC.Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
-
Publication number: 20150346936Abstract: A method for providing professional-level skin care to consumers at home using an integrated system of one or more cosmetic skincare tools, skincare products and a mobile App, where the tool settings/frequency of use and a complementary skincare product regimen (product selection, frequency and order of use) are selected and changed based on user interaction with and data from the tool and/or App.Type: ApplicationFiled: December 2, 2013Publication date: December 3, 2015Inventors: Kathryn P. RODAN, Kathy A. FIELDS, Timothy J. FALLA, Steven D. POWELL
-
Publication number: 20150094270Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: ApplicationFiled: November 3, 2014Publication date: April 2, 2015Applicant: HELIX BIOMEDIX, INC.Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
-
Patent number: 8962798Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: GrantFiled: August 7, 2013Date of Patent: February 24, 2015Assignee: Helix BioMedix, Inc.Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
-
Publication number: 20140066380Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: ApplicationFiled: August 7, 2013Publication date: March 6, 2014Applicant: HELIX BIOMEDIX, INC.Inventors: Scott M. HARRIS, Timothy J. FALLA, Lijuan ZHANG
-
Patent number: 8658764Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: GrantFiled: December 29, 2011Date of Patent: February 25, 2014Assignee: Helix Biomedix, Inc.Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
-
Patent number: 8597902Abstract: Short peptides having biological and therapeutic activity are disclosed. Specifically, the activity of the disclosed peptides is directed to reducing or protecting against mutagen-induced cellular/tissue toxicity (i.e., chemopreventive). For example, the disclosed peptides protect against skin toxicity and/or mutagenesis that occurs from ultraviolet (UV) light exposure. The disclosed peptides also block the activation of certain cell cycle regulatory proteins such as Chk2. An example of such a peptide is Ser-Leu-Tyr-Gln-Ser (SEQ ID NO: 10). The disclosed peptides are also useful for methods of reducing or protecting against cellular toxicity and mutation accumulation that would otherwise occur following mutagen exposure. One such method is drawn to applying a peptide to the skin to prevent or reduce mutagenic damage resulting from UV light (e.g., sunlight) exposure.Type: GrantFiled: November 18, 2010Date of Patent: December 3, 2013Assignee: Helix Biomedix, Inc.Inventors: Lijuan Zhang, Timothy J. Falla
-
Publication number: 20130096143Abstract: The invention relates to small molecules having biological and therapeutic activity. Particularly, the invention relates to small molecules having lipolytic and anti-adipogenic activity. Two examples of such molecules are 4-methyl-2-(octanoylamino) pentanoic acid and N-isopentyloctanamide. The invention further relates to methods of preventing or treating skin conditions such as cellulite using small molecules having lipolytic and anti-adipogenic activity.Type: ApplicationFiled: June 28, 2011Publication date: April 18, 2013Applicant: HELIX BIOMEDIX, INC.Inventors: Timothy J. Falla, Lijuan Zhang
-
Publication number: 20120225023Abstract: Short peptides having biological and therapeutic activity are disclosed. Specifically, the activity of the disclosed peptides is directed to reducing or protecting against mutagen-induced cellular/tissue toxicity (i.e., chemopreventive). For example, the disclosed peptides protect against skin toxicity and/or mutagenesis that occurs from ultraviolet (UV) light exposure. The disclosed peptides also block the activation of certain cell cycle regulatory proteins such as Chk2. An example of such a peptide is Ser-Leu-Tyr-Gln-Ser (SEQ ID NO: 10). The disclosed peptides are also useful for methods of reducing or protecting against cellular toxicity and mutation accumulation that would otherwise occur following mutagen exposure. One such method is drawn to applying a peptide to the skin to prevent or reduce mutagenic damage resulting from UV light (e.g., sunlight) exposure.Type: ApplicationFiled: November 18, 2010Publication date: September 6, 2012Applicant: HELIX BIOMEDIX, INC.Inventors: Lijuan Zhang, Timothy J. Falla
-
Publication number: 20120093740Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: ApplicationFiled: December 29, 2011Publication date: April 19, 2012Applicant: HELIX BIOMEDIX, INC.Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
-
Patent number: 8110658Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.Type: GrantFiled: June 12, 2007Date of Patent: February 7, 2012Assignee: Helix BioMedix, Inc.Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
-
Patent number: 8071555Abstract: The disclosed invention provides tetrapeptides with the amino acid sequence proline-glutamine-glutamate-X (P-Q-E-X), where X can be either lysine (K) or isoleucine (I). These tetrapeptides inhibit ultraviolet light (UV)-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) by skin epithelial cells and fibroblasts. Furthermore, the tetrapeptides repress the upregulation of matrix metalloproteinase-1 (MMP-1) by skin fibroblasts induced by either direct exposure to UV rays or treatment with media conditioned by UV-treated keratinocytes. The small size and bio-activity of the tetrapeptides render them suitable for use in therapies directed to inflammatory skin disorders and as active ingredients in skin care products.Type: GrantFiled: October 28, 2008Date of Patent: December 6, 2011Assignee: Helix BioMedix Inc.Inventors: Lijuan Zhang, Scott M. Harris, Timothy J. Falla
-
Patent number: 7696174Abstract: Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these effects, the disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed.Type: GrantFiled: December 27, 2007Date of Patent: April 13, 2010Assignee: Helix Biomedix, Inc.Inventors: Scott M. Harris, Lijuan Zhang, Timothy J. Falla
-
Publication number: 20090142280Abstract: The disclosed invention provides tetrapeptides with the amino acid sequence proline-glutamine-glutamate-X (P-Q-E-X), where X can be either lysine (K) or isoleucine (I). These tetrapeptides inhibit ultraviolet light (UV)-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) by skin epithelial cells and fibroblasts. Furthermore, the tetrapeptides repress the upregulation of matrix metalloproteinase-1 (MMP-1) by skin fibroblasts induced by either direct exposure to UV rays or treatment with media conditioned by UV-treated keratinocytes. The small size and bio-activity of the tetrapeptides render them suitable for use in therapies directed to inflammatory skin disorders and as active ingredients in skin care products.Type: ApplicationFiled: October 28, 2008Publication date: June 4, 2009Inventors: Lijuan Zhang, Scott Harris, Timothy J. Falla
-
Publication number: 20080206160Abstract: Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these effects, the disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed.Type: ApplicationFiled: December 27, 2007Publication date: August 28, 2008Inventors: Scott M. Harris, Lijuan Zhang, Timothy J. Falla
-
Patent number: 7407940Abstract: The invention encompasses hexapeptides consisting of alternating hydrophobic residues (B) at positions 2, 4, and 6, hydrophilic, charged residues (X) at positions 1 and 3, and a naphthylalanine (Nal), an aliphatic or aromatic residue (O) at position five, represented generally by the formula XBXBOB, which exhibit antimicrobial activity against infections caused by a variety of pathogens. These pathogens may include gram positive or negative bacteria, acid-fast bacteria such as mycobacteria, parasites, dermatophytes, or fungal pathogens. Typical fungal pathogens include Candida albicans and typical dermatophytes include Trichophyton rubrum and Trichophyton mentagrophytes. The hexapeptides of the present invention exhibit antifungal activity, antibacterial activity, desirable stability, and lack toxicity to the mammal receiving treatment.Type: GrantFiled: February 8, 2006Date of Patent: August 5, 2008Assignee: Helix BioMedix Inc.Inventors: Timothy J. Falla, Lijuan Zhang, Scott M. Harris
-
Patent number: 7390873Abstract: A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X1X1PX2X3X2P(X2X2P)nX2X3(X5)0; (SEQ ID NO:23) X1X1PX2X3X4(X5)rPX2X3X3; (SEQ ID NO:24) X1X1X3(PW)uX3X2X5X2X2X5X2(X5)0; and (SEQ ID NO:25) X1X1X3X3X2P(X2X2P)nX2(X5)m; (SEQ ID NO:26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine X3 represents Arginine or Lysine; X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.Type: GrantFiled: March 28, 2003Date of Patent: June 24, 2008Assignee: University of British ColumbiaInventors: Timothy J. Falla, Robert E. W. Hancock, Monisha Gough